Hemp products, EU law and the Irish courts

Members of Hemp Federation Ireland continue to face criminal charges and regulatory restrictions arising from the possession, sale or licensed cultivation of low-THC industrial hemp and hemp-derived products that they contend are lawful under EU agricultural and free-movement rules.

One of the longer-running High Court challenges is JP O’Brien v Director of Public Prosecutions & Ors (Record Number 2020/946 JR). The applicant JP O’Brien operates Little Collins CBD Dispensary in Galway and was charged after Gardaí seized material (mostly described as leaf tea) from the business premises and his home in 2019. Laboratory results indicated that the products tested were below 0.2 % THC. The amended Statement of Grounds seeks to restrain the prosecution and argues that Irish practice of treating almost the entire plant (other than mature stalk, fibre and separated seed) as a controlled drug is inconsistent with Regulation (EU) No 1307/2013, Articles 34–36 TFEU and the Court of Justice decision in Kanavape (Case C-663/18). Leave was granted; No trial date has been fixed; the court has indicated a possible three-day hearing window in the first or second quarter of 2027.

A further pair of proceedings involves James Weathers and Deborah Weathers of the shop Puff n Stuff. Criminal proceedings are before Cork Circuit Criminal Court (ref. CYDP0033/2021). Parallel judicial review proceedings are in the High Court (ref. 2021/166 JR). The charges relate to domestic sales of imported industrial hemp flowers, buds and leaves. The Hemp Federation Members state that the material was sourced from EU-catalogue varieties lawfully grown under licence in another Member State, with THC at or below the applicable EU limit. Their position is that the products are lawfully produced licensed industrial hemp — an agricultural crop — and not a narcotic drug. They rely on the Court of Justice decision in Kanavape, on the free-movement rules in Articles 34 and 36 TFEU, and on pending references before the Court of Justice that concern restrictions on the marketing of hemp flowers, leaves and related derivatives. Both sets of proceedings remain active. The State has on more than one occasion offered to waive legal costs if the applicants withdraw the judicial review; those offers have been declined. The judicial review is understood to be adjourned into November 2026.

A third set of proceedings is the judicial review Marcus John McCabe and Catherine Mullaney v Minister for Health & Ors (High Court Record No. H.JR.2025/1699). The applicants challenge the regime that confines licensed cultivation of industrial hemp (EU Common Catalogue varieties compliant with CAP rules) to fibre and requires leaves and flowering tops to be destroyed. They contend that the relevant Misuse of Drugs Statutory Instruments (including S.I. 210/2022 and S.I. 211/2022) and associated licensing conditions are technical regulations within the meaning of Directive (EU) 2015/1535 (the Single Market Transparency Directive). They say the instruments were not notified in draft to the European Commission as required by Article 5 and that, if they are technical regulations, they are inapplicable against the applicants under the case law of the Court of Justice (CIA Security and Unilever). The State’s position is that the instruments are drugs-control measures concerning possession of controlled substances and do not fall within the Directive. The High Court has fixed a two day hearing on the 11th March next for the substantive Judicial Review.

A further member, Brendan O’Mara, faces a charge of possession of cannabis for sale or supply contrary to section 15A of the Misuse of Drugs Act 1977 following a seizure of material at his home in County Clare in May 2025. He has pleaded not guilty. The District Court has adjourned the prosecution while the High Court considers whether hemp at or below 0.3 % THC can lawfully be treated as a Schedule 1 controlled drug, whether it is an agricultural good, and whether the Irish framework is compatible with EU law. The Chief State Solicitor’s Office has obtained an adjournment of the declaratory proceedings pending the outcome of the Italian and Dutch references before the Court of Justice; the applicant has liberty to re-enter at any stage. Brendan O’Mara is also seeking a variation of his bail conditions. An application listed for hearing was delayed pending permission from the Court of Criminal Appeal for the High Court to hear the variation request. Hemp Federation Ireland has already published a statement on the public framing of these proceedings (10 September 2026). That statement records HFI’s position that hemp within EU parameters is an agricultural product and that the organisation does not express a view on the merits of the criminal charge.

Further proceedings concern James McDonald and related parties connected with The Hemp Company, 167 Capel Street, Dublin 1. Charges under sections 3 and 15 of the Misuse of Drugs Act 1977 arise from a Garda search of the premises on 10 July 2018. Products seized included commercially packaged items described with names such as Girl Scout Cookies, Super Lemon Haze, Kerala Gold and similar varieties; Forensic Science Ireland certified a number of them as cannabis resin. The operators’ recorded position, is that the items were low-THC products (stated as 0.2 % THC) manufactured in the EU, purchased on the understanding that they were lawful under EU rules, and intended as an agricultural or CBD product rather than a narcotic. Two related matters remain active. One is listed for DPP directions; the defence position advanced is that the material is an agricultural crop under EU regulation. A second (Bill number 234/2026) is listed for arraignment in the Circuit Court on 9 December 2026; the argument put forward relies on EU Regulation 1307/2013 and related authority. These proceedings remain at the directions and arraignment stages.

A further member has proceedings in the Circuit Court Waterford arising from the possession of EU-approved low-THC hemp biomass (principally flower), grown under licence in another member state, together with compressed plant material from a licensed Irish grow and CBD distillate. The charges are brought under the Misuse of Drugs Act 1977. The matter remains before the Circuit Court. The member has requested that further details not be published while the proceedings are live. The court adjourned the matter on 17 November 2026 until 15 December 2026.

The practical effect of the current Irish approach has been to confine licensed industrial hemp almost entirely to a fibre-only model. Leaves and flowering tops must be destroyed, finished products containing any detectable THC are treated as controlled drugs, and operators who seek to use the whole plant face seizures and prosecutions. As a result, a large part of the commercial sector that existed since the early noughties have closed, licensed cultivation has contracted to a very small area, and the crop’s potential contribution to the bioeconomy — fibre and materials, soil carbon, and rural diversification under the Common Agricultural Policy — has not been realised. The cases outlined above are the legal expression of that practical restriction: they ask whether an EU-approved agricultural crop can continue to be administered as a Schedule 1 drug when the State has not shown that the restriction is required by public-health risk and has not notified the relevant measures under the Single Market Transparency Directive or any other mechanism.

Hemp Federation Ireland’s interest in these cases is limited to the regulatory treatment of licensed industrial hemp as a whole crop under EU agricultural and single-market rules.

The Council’s October 2026 position on hemp;

On 19 October 2026 the Council of the European Union agreed a partial negotiating mandate on amendments to Regulation (EU) No 1308/2013 (the Common Market Organisation Regulation). The text, published as Council Document ST-14647-2026-INIT, expands the flax and hemp sector beyond raw fibre and seed to cover other parts of the plant, including flowers, leaves and biomass. It sets a uniform maximum of 0.3 % Δ9-THC for varieties listed in the EU Common Catalogue and requires certified seed. The accompanying recitals record that products from such low-THC varieties are not narcotic drugs on current scientific knowledge, that divergent national prohibitions on specific hemp products can undermine the common market organisation and create barriers to trade, and that whole-plant biomass offers environmental and economic opportunities beyond fibre.

Growing efforts are made to establish domestic processing of industrial hemp straw into hurd and fibre for construction, insulation, animal bedding, textiles and other uses, with the aim of creating a contracted route to market for Irish growers. The regulatory treatment of the whole plant continues to shape commercial prospects. In July 2026 representatives of a west-of-Ireland initiative appeared before the Oireachtas Joint Committee on Agriculture and Food and set out plans to invest in decortication infrastructure. When asked when the equipment would be in place, the response given was that it was intended for the current year, with processing of the following year’s crop expected. Simultaneously, regulators have refused an application for hemp silage and steam pre-treatment on the ground that ensiling would increase THC concentration. These incidents sit within the wider pattern of treating low-THC catalogue hemp as controlled material rather than as an agricultural crop available for whole-plant uses.

Related interest has been expressed in a larger manufacturing facility that would depend on a reliable domestic supply of processed hemp hurd (roughly 15,000 tonnes annually, or approximately 2,400 hectares of crop) and would support related processing infrastructure and jobs. Committee hearings and industry submissions have repeatedly highlighted the absence of domestic commercial-scale decortication facilities as a major barrier. Cultivation has fallen sharply, to around 11 hectares registered in 2026. HFI maintains that the decline is driven by the regulatory treatment of low-THC industrial hemp under controlled-drugs rules, including the requirement that leaves and flowering tops be destroyed. That same treatment has prevented the emergence of domestic commercial-scale processing capacity, so the absence of infrastructure is a consequence of the regulatory regime rather than an independent cause of the drop in cultivation. Whole-crop utilisation therefore remains constrained by licensing conditions and the supply-chain gaps that follow from them.

HFI’s interest is limited to the regulatory status of low-THC industrial hemp under EU agricultural and single-market rules.

Next
Next

Official X Account Update